BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33133861)

  • 1. Integration of Next-Generation Sequencing in Diagnosing and Minimal Residual Disease Detection in Patients With Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
    Sherali N; Hamadneh T; Aftab S; Alfonso M; Tsouklidis N
    Cureus; 2020 Sep; 12(9):e10696. PubMed ID: 33133861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
    Gupta DG; Varma N; Abdulkadir SA; Sreedharanunni S; Sachdeva MUS; Naseem S; Bose P; Binota J; Malhotra P; Khadwal A; Trehan A; Varma S
    Cancer; 2024 Mar; 130(5):713-726. PubMed ID: 37819686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
    Short NJ; Jabbour E; Macaron W; Ravandi F; Jain N; Kanagal-Shamanna R; Patel KP; Loghavi S; Haddad FG; Yilmaz M; Issa GC; Kebriaei P; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Kantarjian H
    Am J Hematol; 2023 Aug; 98(8):1196-1203. PubMed ID: 37183966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
    Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
    Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia.
    Tang GS; Wu J; Liu M; Chen H; Gong SG; Yang JM; Hu XX; Wang JM
    Am J Transl Res; 2015; 7(3):632-9. PubMed ID: 26045902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options.
    Khan M; Siddiqi R; Tran TH
    Semin Hematol; 2018 Oct; 55(4):235-241. PubMed ID: 30502852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
    Kotrova M; Trka J; Kneba M; Brüggemann M
    Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation.
    Zhao X; Zhao X; Chen H; Qin Y; Xu L; Zhang X; Liu K; Huang X; Chang YJ
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1936-1943. PubMed ID: 29572111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
    Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R
    Front Oncol; 2019; 9():726. PubMed ID: 31448230
    [No Abstract]   [Full Text] [Related]  

  • 10. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?
    Tran TH; Tasian SK
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101331. PubMed ID: 34865703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Short NJ; Jabbour E; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2024 Feb; ():. PubMed ID: 38485650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic efficacy for measurement of real-time quantitative PCR-based major bcr/abl mRNA in patients with Philadelphia chromosome-positive leukemia].
    Takahata M; Hashino S; Fujisawa F; Kondo T; Ota S; Kobayashi S; Tanaka J; Imamura M; Asaka M
    Rinsho Ketsueki; 2004 Dec; 45(12):1241-6. PubMed ID: 15678915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
    Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
    Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
    J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis of adult Philadelphia chromosome-like acute lymphoblastic leukemia by fluorescence in situ hybridization].
    Lin DN; Li QL; He XJ; Li H; Liao LB; He H; Zhou LL; Li Z; Liu XL; Liu QF; Zhou HS; Cao R
    Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):749-755. PubMed ID: 33113607
    [No Abstract]   [Full Text] [Related]  

  • 17. Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing.
    Szankasi P; Schumacher JA; Kelley TW
    Ann Hematol; 2016 Jan; 95(2):201-10. PubMed ID: 26555285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
    Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
    Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
    Pfeifer H; Cazzaniga G; van der Velden VHJ; Cayuela JM; Schäfer B; Spinelli O; Akiki S; Avigad S; Bendit I; Borg K; Cavé H; Elia L; Reshmi SC; Gerrard G; Hayette S; Hermanson M; Juh A; Jurcek T; Chillón MC; Homburg C; Martinelli G; Kairisto V; Lange T; Lion T; Mueller MC; Pane F; Rai L; Damm-Welk C; Sacha T; Schnittger S; Touloumenidou T; Valerhaugen H; Vandenberghe P; Zuna J; Serve H; Herrmann E; Markovic S; Dongen JJMV; Ottmann OG
    Leukemia; 2019 Aug; 33(8):1910-1922. PubMed ID: 30858550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India.
    Gupta DG; Varma N; Sharma P; Truica MI; Abdulkadir SA; Singh P; Singh Sachdeva MU; Naseem S; Siddiqui MR; Bose P; Binota J; Malhotra P; Khadwal A; Trehan A; Varma S
    Cancer; 2023 Nov; 129(21):3390-3404. PubMed ID: 37498973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.